Generating a broad portfolio of novel agents with best-in-class potential.
Development Pipeline
Driving meaningful advances to address chronic inflammation.
We’re committed to evolving immunology, with a pipeline that includes programs specifically targeted to address inflammatory diseases demonstrating clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell and T-cell activity shows promise in multiple established patient populations.
Program
Target
Indication
- Discovery
- Pre-Clinical
- Phase 1
- Phase 2
- Phase 3
MRGPRX2
Chronic Inducible Urticaria
Chronic Spontaneous Urticaria
Atopic Dermatitis/Inflammatory Itch
Other Indications
Program
Target
MRGPRX2
Indication
Stage
Chronic Inducible Urticaria
Chronic Spontaneous Urticaria
Atopic Dermatitis/Inflammatory Itch
Other Indications
Phase 2
Phase 1
Phase 1
Phase 1
Program
Target
IL-18
Indication
Stage
Atopic Dermatitis
Other Indications
Phase 1
Pre-Clinical
Pre-Clin.
Program
Target
PKCϴ
Indication
Stage
Inflammatory Bowel Disease
Discovery
Discov.